A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2022-08-17
Adverse events
Grade 2 Colitis — outcome: RECOVERED/RESOLVED; onset 2022-11-15 (study day 73); relationship: Y
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 149); relationship: N
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-04-28 (study day 237); relationship: N
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-06-29 (study day 299); relationship: not assessed
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-22 (study day 475); relationship: not assessed; serious criteria: life-threatening
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-12-23 (study day 476); relationship: N
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-01-17 (study day 501); relationship: N
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-03-05 (study day 549); relationship: not assessed
Data queries
No data queries.